News
A recipient of the 2025 Elite Trial Lawyers Lifetime Achievement Award, Morgan & Morgan's John Yanchunis spoke with the National Law Journal about his storied career, from bringing one of the nation’s ...
13hon MSN
Penn CRISPR science is the foundation for a gene-editing heart disease treatment under Eli Lilly
Penn's Kiran Musunuru spoke with The Inquirer about the future of CRISPR technology.
11h
Medindia on MSNSingle Life Spiced Up With GLP-1 Weight Loss Drugs?
In addition to the psychological and social impacts, GLP-1 drugs may also influence hormonal balance. Studies show that ...
17h
The Chosun Ilbo on MSNS. Korean companies join global race for obesity drugs
As the global obesity medication market skyrockets, South Korean pharmaceuticals are rushing to develop national obesity ...
GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little evidence of improving cardiorespiratory fitness, researchers say.
Market OutlineThe Global Weight Loss Drugs Market is valued at USD 2.88 Billion in 2024 and is projected to reach a value ...
Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results